Kenvue Inc.
KVUEAPI behind this page
KVUE Q4 2025 request
Playground key active
/api/financials?ticker=KVUE&year=2025&quarter=4
Pick an endpoint and run the request.Income Statement
| Metric | Q4 2025 | Q4 2024 | YoY |
|---|---|---|---|
| Revenue | 3,780 | 3,662 | +3.2% |
Show Business Segments breakouts |
|||
| Essential Health | 1,148 | 1,082 | +6.1% |
| Self Care | 1,592 | 1,569 | +1.5% |
| Skin Health and Beauty | 1,040 | 1,011 | +2.9% |
| Cost of Revenue | 1,643 | 1,592 | +3.2% |
Show Counterparty Name breakouts |
|||
| Johnson & Johnson | 43 | 50 | -14.0% |
Show Restructuring Plan breakouts |
|||
| 2024 Multi-Year Restructuring Initiative | 16 | 8 | +100.0% |
| Gross Profit | 2,137 | 2,070 | +3.2% |
| Selling, General & Administrative | 1,535 | 1,525 | +0.7% |
Show Restructuring Plan breakouts |
|||
| 2024 Multi-Year Restructuring Initiative | 1 | 2 | -50.0% |
| Restructuring Charges | 86 | 65 | +32.3% |
Show Restructuring Plan breakouts |
|||
| 2024 Multi-Year Restructuring Initiative | 86 | 65 | +32.3% |
| Other Operating Income Expense Net | -42 | -3 | -1300.0% |
| Operating Income | 535 | 483 | +10.8% |
| Non-Operating Income (Expense) | 10 | 42 | -76.2% |
| Interest Income Expense Nonoperating Net | 98 | 95 | +3.2% |
| Income Before Taxes | 427 | 346 | +23.4% |
| Income Tax Expense (Benefit) | 97 | 53 | +83.0% |
| Net Income | 330 | 293 | +12.6% |
Show Equity Components breakouts |
|||
| Retained Earnings | 330 | 293 | +12.6% |
Show Consolidated Entities breakouts |
|||
| Variable Interest Entity Primary Beneficiary | 6 | 5 | +20.0% |
Show Related Party Transaction breakouts |
|||
| Net Economic Benefit Arrangements · Parent | 2 | 11 | -81.8% |
| EPS (Basic) | 0.18 | 0.16 | +12.5% |
| EPS (Diluted) | 0.17 | 0.16 | +6.3% |
| Wtd Avg Shares (Basic) | 0 | 0 | — |
| Wtd Avg Shares (Diluted) | -1 | 2 | -150.0% |
| Research & Development | 98 | 106 | -7.5% |
| Other Non-Operating Income (Expense) | 1 | -3 | +133.3% |
| Comprehensive Income | 501 | -494 | +201.4% |
| Other Comprehensive Income | 171 | -787 | +121.7% |
Show Equity Components breakouts |
|||
| Accumulated Defined Benefit Plans Adjustment | 6 | 38 | -84.2% |
| Accumulated Other Comprehensive Income | 171 | -787 | +121.7% |
| Accumulated Translation Adjustment | 178 | -824 | +121.6% |
| Gain (Loss) on Derivatives and Hedges | -13 | -1 | -1200.0% |
Balance Sheet
| Metric | Q4 2025 | Q4 2024 | YoY |
|---|---|---|---|
| Current Assets | |||
| Cash & Cash Equivalents | 1,062 | 1,070 | -0.7% |
| Accounts Receivable | 2,382 | 2,165 | +10.0% |
| Inventory | 1,666 | 1,591 | +4.7% |
| Prepaid Expenses & Other Current Assets | 432 | 494 | -12.6% |
Show Counterparty Name breakouts |
|||
| Johnson & Johnson | 21 | 109 | -80.7% |
| Other Assets Current | 155 | 205 | -24.4% |
| Total Current Assets | 5,697 | 5,525 | +3.1% |
| Non-Current Assets | |||
| Property, Plant & Equipment | 2,212 | 1,849 | +19.6% |
| Goodwill | 9,509 | 8,843 | +7.5% |
Show Business Segments breakouts |
|||
| Essential Health | 1,684 | 1,604 | +5.0% |
| Self Care | 5,562 | 5,054 | +10.1% |
| Skin Health and Beauty | 2,263 | 2,185 | +3.6% |
| Deferred Tax Assets | 237 | 184 | +28.8% |
| Other Non-Current Assets | 727 | 726 | +0.1% |
Show Counterparty Name breakouts |
|||
| Johnson & Johnson | 91 | 78 | +16.7% |
| Total Assets | 27,076 | 25,601 | +5.8% |
| Operating Lease Right-of-Use Assets | 151 | 111 | +36.0% |
Show Counterparty Name breakouts |
|||
| Johnson & Johnson | 26 | 35 | -25.7% |
Show Balance Sheet Location breakouts |
|||
| Other Assets | 151 | 111 | +36.0% |
| Intangible Assets | 3,792 | 3,771 | +0.6% |
Show Finite Lived Intangible Assets By Major Class breakouts |
|||
| Customer Relationships | 871 | 859 | +1.4% |
| Other Intangible Assets | 569 | 582 | -2.2% |
| Patents and trademarks | 2,352 | 2,330 | +0.9% |
| Other Assets | |||
| Intangible Assets Net Excluding Goodwill | 8,694 | 8,474 | +2.6% |
Show Indefinite Lived Intangible Assets By Major Class breakouts |
|||
| Other Intangible Assets | 62 | 55 | +12.7% |
| Trademarks | 4,840 | 4,648 | +4.1% |
| Current Liabilities | |||
| Debt Current | 1,453 | 1,552 | -6.4% |
| Accounts Payable | 2,473 | 2,254 | +9.7% |
Show Related Party Transaction breakouts |
|||
| Net Economic Benefit Arrangements · Parent | 44 | 23 | +91.3% |
| Accrued Liabilities | 1,159 | 1,132 | +2.4% |
| Accrued Rebates Returns And Promotions Current | 755 | 727 | +3.9% |
| Accrued Income Taxes Current | 105 | 74 | +41.9% |
| Total Current Liabilities | 5,945 | 5,739 | +3.6% |
| Commercial Paper | 700 | 800 | -12.5% |
| Current Portion of Long-Term Debt | -750 | -750 | 0.0% |
| Non-Current Liabilities | |||
| Deferred Tax Liabilities | 2,354 | 2,261 | +4.1% |
| Employee Related Liabilities Current And Noncurrent | 340 | 342 | -0.6% |
| Other Non-Current Liabilities | 601 | 536 | +12.1% |
Show Counterparty Name breakouts |
|||
| Johnson & Johnson | 139 | 143 | -2.8% |
| Total Liabilities | 16,311 | 15,933 | +2.4% |
| Operating Lease Liabilities | 107 | 76 | +40.8% |
Show Counterparty Name breakouts |
|||
| Johnson & Johnson | 15 | 24 | -37.5% |
Show Balance Sheet Location breakouts |
|||
| Other Noncurrent Liabilities | 107 | 76 | +40.8% |
| Accrued Income Taxes Noncurrent | 219 | 185 | +18.4% |
| Other Liabilities | |||
| Long Term Debt And Lease Obligation Excluding Current Maturities | 7,071 | 7,055 | +0.2% |
| Stockholders' Equity | |||
| Common Stock | 19 | 19 | 0.0% |
| Additional Paid-In Capital | 16,348 | 16,130 | +1.4% |
| Treasury Stock Common Value | -439 | -242 | -81.4% |
| Retained Earnings | -204 | -93 | -119.4% |
| Accumulated Other Comprehensive Income | -4,959 | -6,146 | +19.3% |
| Total Stockholders' Equity | 10,765 | 9,668 | +11.3% |
Show Equity Components breakouts |
|||
| Accumulated Defined Benefit Plans Adjustment | -125 | -130 | +3.8% |
| Accumulated Other Comprehensive Income | -4,959 | -6,146 | +19.3% |
| Accumulated Translation Adjustment | -4,862 | -6,040 | +19.5% |
| Additional Paid In Capital | 16,348 | 16,130 | +1.4% |
| Common Stock | 19 | 19 | 0.0% |
| Gain (Loss) on Derivatives and Hedges | 28 | 24 | +16.7% |
| Retained Earnings | -204 | -93 | -119.4% |
| Treasury Stock Common | -439 | -242 | -81.4% |
| Total Liabilities & Equity | 27,076 | 25,601 | +5.8% |
Cash Flow Statement
| Metric | YTD Q4 2025 | YTD Q4 2024 | YoY |
|---|---|---|---|
| Operating Activities | |||
| Depreciation & Amortization | 138 | 150 | -8.0% |
Show Business Segments breakouts |
|||
| Essential Health | 59 | 57 | +3.5% |
| Self Care | 50 | 62 | -19.4% |
| Skin Health and Beauty | 29 | 31 | -6.5% |
| Stock-Based Compensation | 30 | 54 | -44.4% |
| Deferred Income Taxes | -97 | -40 | -142.5% |
| Other Non-Cash Items | 13 | 33 | -60.6% |
| Change in Accounts Receivable | 35 | 125 | -72.0% |
| Change in Inventory | 132 | 169 | -21.9% |
| Increase Decrease In Other Operating Assets | -25 | -46 | +45.7% |
| Increase Decrease In Accounts Payable And Accrued Liabilities | 130 | 37 | +251.4% |
| Increase Decrease In Employee Related Liabilities | 26 | 22 | +18.2% |
| Increase Decrease In Accrued Taxes Payable | 53 | -70 | +175.7% |
| Increase Decrease In Other Operating Liabilities | 66 | 25 | +164.0% |
| Net Cash from Operations | 854 | 793 | +7.7% |
| Investing Activities | |||
| Capital Expenditures | -110 | -132 | +16.7% |
| Other Investing Activities | 11 | 6 | +83.3% |
| Net Cash from Investing | -75 | -132 | +43.2% |
| Financing Activities | |||
| Proceeds From Repayments Of Commercial Paper | -470 | -101 | -365.3% |
| Payments Of Dividends | -398 | -393 | -1.3% |
| Share Repurchases | 0 | -121 | +100.0% |
| Proceeds From Payments For Other Financing Activities | -1 | 28 | -103.6% |
| Net Cash from Financing | -869 | -587 | -48.0% |
| Other Cash Flow | |||
| Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 13 | -61 | +121.3% |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 1,062 | 1,070 | -0.7% |
| Net Change in Cash | -77 | 13 | -692.3% |
Values in millions USD. Source: SEC EDGAR 10-K filing.